|Assessment Status||Assessment Process Complete|
|Indication||For the treatment of major depressive disorder.|
|Full submission received from Applicant||01/04/2009|
|NCPE assessment completed||03/09/2009|
|NCPE assessment outcome||Reimbursement not recommended|
3rd September 2009 – At the current price agomelatine (Valdoxan®) is not considered cost-effective for the treatment of major depressive episodes under the Community Drugs Schemes.
11th December 2009 – Following a revision in price application we now consider agomelatine (Valdoxan®) cost effective under the Community Drugs schemes. The product will now be added to the list of items reimbursable under the schemes.